# A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

> **NCT00730847** · PHASE4 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 743 (actual)

## Conditions studied

- Human Papillomavirus Infection Leading to Cervical Cancer

## Interventions

- **BIOLOGICAL:** Cervarix

## Key facts

- **NCT ID:** NCT00730847
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-17
- **Primary completion:** 2012-01-16
- **Final completion:** 2012-01-16
- **Target enrollment:** 743 (ACTUAL)
- **Why stopped:** GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study.
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730847, "A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00730847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*